4.6 Article

SafeFit Trial: virtual clinics to deliver a multimodal intervention to improve psychological and physical well-being in people with cancer. Protocol of a COVID-19 targeted non-randomised phase III trial

期刊

BMJ OPEN
卷 11, 期 8, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-048175

关键词

oncology; adult oncology; public health; rehabilitation medicine

资金

  1. Macmillan Cancer Support
  2. Wessex Cancer Alliance
  3. National Lottery (Digital, Culture Media and Sport) [20142065]
  4. Clinical Research Network
  5. National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust
  6. Institute of Cancer Research, London
  7. NIHR Senior Investigator Scheme
  8. NIHR Southampton Biomedical Research Centre
  9. National Institute for Health Research through the NIHR Southampton Biomedical Research

向作者/读者索取更多资源

The study aims to investigate whether a multimodal intervention delivered virtually by cancer exercise specialists can improve physical and emotional functionings of individuals with cancer during the COVID-19 pandemic.
Introduction The impact of the COVID-19 pandemic (caused by the SARS-CoV-2 virus) on individuals with cancer has been profound. It has led to increased anxiety, distress and deconditioning due to reduced physical activity. We aim to investigate whether SafeFit, a multimodal intervention of physical activity, nutrition and psychological support delivered virtually by cancer exercise specialists (CES), can improve physical and emotional functionings during the COVID-19 pandemic. Methods and analysis A phase III non-randomised intervention trial, target recruitment of 1050 adults with suspected or confirmed diagnosis of cancer. All recruited participants will receive the multimodal intervention delivered by CES for 6 months. Sessions will be delivered 1-to-1 using telephone/video conferencing consultations. CES will work with each participant to devise a personalised programme of (1) physical activity, (2) basic dietary advice and (3) psychological support, all underpinned by behaviour change support. Primary outcome Physical and emotional functioning as measured by the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ-C30). Secondary outcomes: overall quality of life measured by EORTC-QLQ-C30 and EQ-5D-5L, health economics, patient activation, self-efficacy to self-manage chronic disease, distress, impact of COVID-19 on emotional functioning, self-reported physical activity, functional capacity and nutrition. Adherence to the intervention will also be measured and a process evaluation conducted. Ethics and dissemination Ethical approval was obtained from the Health Research Authority (reference number 20/NW/0254). Results of this trial will be disseminated through publication of peer-reviewed articles, presentations at scientific conferences, and to the public and people with cancer in collaboration with our patient and public involvement representatives and partners.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据